IGF1R and Ewing sarcoma: In a recent phase I trial of a fully human IgG2 monoclonal antibody targeting the insulin-like growth-factor-1 receptor, figitumumab, a number of patients with refractory, advanced ES/PNET responded unexpectedly well [14].